Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.
| Revenue (Most Recent Fiscal Year) | $178.03M |
| Net Income (Most Recent Fiscal Year) | $-70.81M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -36.89% |
| Net Margin (Trailing 12 Months) | -38.91% |
| Return on Equity (Trailing 12 Months) | -163.73% |
| Return on Assets (Trailing 12 Months) | -23.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 4.24 |
| Inventory Turnover (Trailing 12 Months) | 0.18 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.27 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 265.05M |
| Free Float | 231.28M |
| Market Capitalization | $72.39M |
| Average Volume (Last 20 Days) | 1.59M |
| Beta (Past 60 Months) | 2.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.74% |
| Percentage Held By Institutions (Latest 13F Reports) | 31.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |